Notice of Early Expiration of Notices of Funding Opportunities Related to the Simplified Review Framework for NIH Research Grant Applications
Notice Number:
NOT-OD-25-113
Key Dates
Release Date:
May 15, 2025
Related Announcements
- April 4, 2024 - Simplified Review Framework for NIH Research Project Grant Applications - Update and Implementation Plans. See Notice NOT-OD-24-085
- October 19, 2023 – Simplified Review Framework for NIH Research Project Grant Applications. See Notice NOT-OD-24-010.
Issued by
Office of The Director, National Institutes of Health (OD)
Purpose
On October 19, 2023, NIH announced a new framework for the peer review of most research project grant (RPG) applications. We have identified a number of Notices of Funding Opportunities (NOFOs) that were not expired or reissued as indicated in the implementation plan outlined in NOT-OD-24-085. Consequently, we will expire the listed NOFOs at the end of the current application cycle (May 24, 2025). We will accept R01, R21 and R34 continuous submission applications intended for the standard May 7, 2025 AIDS due date through June 1, 2025 (end of the standard continuous submission receipt period). No applications for due dates on or after May 25, 2025 will be accepted.
| Funding Opportunity Number (FON) | Funding Opportunity Title |
| PAR-24-100 | NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) |
| PAR-24-231 | Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional) |
| PAR-24-145 | Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) |
| PAR-24-144 | Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) |
| PAR-24-112 | Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) |
| PAR-24-111 | Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) |
| PAR-24-059 | Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional) |
| RFA-NS-24-019 | HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) |
| PAR-24-075 | Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) |
| PAR-24-076 | Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required) |
| RFA-OD-24-010 | Building Sustainable Software Tools for Open Science (R03 Clinical Trial Not Allowed) |
| PAR-24-064 | Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) |
| RFA-MH-25-171 | BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R21 Clinical Trial Optional) |
| RFA-MH-25-170 | BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) |
| RFA-DA-24-041 | BRAIN Initiative: Brain-Behavior Quantification and Synchronization Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trials Not Allowed) |
| RFA-DA-24-040 | BRAIN Initiative: Brain-Behavior Quantification and Synchronization Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional) |
| RFA-ES-24-005 | CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed) |
| PAR-23-297 | Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed) |
| PAR-23-296 | Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed) |
| PAR-23-255 | Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) |
| RFA-DA-24-033 | Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional) |
| RFA-DA-24-032 | Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required) |
| RFA-MH-25-136 | Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional) |
| RFA-MH-25-130 | Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required) |
| RFA-MH-22-185 | NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional) |
| PAR-24-051 | NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required) |
| RFA-DA-24-034 | Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required) |
| RFA-DA-24-031 | Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional) |
| PAR-23-169 | Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) |
| RFA-AI-23-023 | International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) |
| PAR-22-198 | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional) |
| PAR-22-131 | Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) |
| PAR-22-199 | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional) |
| PAR-22-243 | Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) |
| PAR-22-210 | Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional) |
| PAR-22-242 | Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) |
| PAR-23-144 | STrengthening Research Opportunities for NIH Grants (STRONG): Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not A |
| RFA-DC-24-001 | BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Basic Experimental Studies with Humans Required) |
| PAR-23-191 | HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) |
| RFA-MD-24-003 | Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required) |
| PAR-23-190 | Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional) |
| RFA-MD-24-005 | Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed) |
| PAR-23-060 | Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional) |
| PAR-23-061 | Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) |
| PAR-23-062 | Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) |
| PAR-23-084 | Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) |
| RFA-DA-24-066 | HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional) |
| RFA-DA-24-067 | HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional) |
| PAR-24-240 | Genetic Architecture of Mental Disorders in Ancestrally Varied Populations II (U01 Clinical Trial Not Allowed) |
| PAR-23-158 | Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) |
| PAR-23-157 | Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) |
| PAR-23-111 | NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) |
| PAR-23-148 | Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) |
| PAR-23-206 | NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) |
| PAR-24-041 | Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial Not Allowed) |
Inquiries
Please direct all inquiries to:
Department of Health
and Human Services (HHS)
and Human Services (HHS)
